Lantheus Holdings, Inc.
LNTH
Classement en actions
#2849
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the... Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Prix de l'action
$100.02
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$6.53B
Changement (1 jour)
0.32%
Changement (1 an)
76.71%
Pays
US
Échange Lantheus Holdings, Inc. (LNTH)
Catégorie
Healthcare
Bénéfices pour Lantheus Holdings, Inc. (LNTH)
Bénéfices en Jun 2026 TTM : $362.98M
Selon les derniers rapports financiers de Lantheus Holdings, Inc., les bénéfices actuels de l'entreprise sont de $362.98M. En 2023, l'entreprise a réalisé un bénéfice de $410.94M, une augmentation par rapport à celui de 2022 qui était de $26.72M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Lantheus Holdings, Inc. de 2011 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $362.98M | -15.78% |
| 2024 | $430.98M | 4.88% |
| 2023 | $410.94M | 1,438.02% |
| 2022 | $26.72M | -135.61% |
| 2021 | $-75.04M | 553.70% |
| 2020 | $-11.48M | -140.10% |
| 2019 | $28.63M | -42.22% |
| 2018 | $49.55M | 25.00% |
| 2017 | $39.64M | 40.10% |
| 2016 | $28.29M | -340.23% |
| 2015 | $-11.78M | 397.80% |
| 2014 | $-2.37M | -96.09% |
| 2013 | $-60.54M | 42.26% |
| 2012 | $-42.56M | -19.97% |
| 2011 | $-53.18M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 386.13% |
IN
|
